Dr. Rui Tong 佟锐
Chief Physician
Gynecology (III), Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive diagnosis and treatment of gynecologic malignancies, including cervical, ovarian, endometrial, sarcoma, vulvar, and vaginal cancers.
Dr. Rui Tong is a Chief Physician specializing in the diagnosis and treatment of benign and malignant gynecologic tumors. Clinical focus includes early diagnosis, early treatment, and early screening.
Professional roles
- Secretary, Gynecologic Oncology Professional Committee, Liaoning Anti-Cancer Association
- Member, Gynecology Professional Committee, Liaoning Association of Integrative Traditional Chinese and Western Medicine
- Member, Obstetrics and Gynecology Basic and Clinical Immunology Professional Committee, Liaoning Immunology Society
- Standing Committee Member, Reproductive Medicine Professional Committee, Liaoning Association of Integrative Traditional Chinese and Western Medicine
Name order: in Chinese the family name comes first (Tong Rui). Papers usually list the name as Rui Tong or Tong R.
Selected publications
12 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Cell Biochem, 2026 (senior author): RNF125 promotes CD8 T cell-mediated anticancer immunity and suppresses the malignant phenotype of cervical cancer. PubMed 41824200
- Cell Mol Life Sci, 2026 (senior author): LILRB4 shapes an immunosuppressive microenvironment to drive cervical cancer progression through tumor-infiltrating myeloid cell expansion and CD8(+) T-cell suppression. PubMed 41776053
- Reprod Sci, 2022 (senior author): Circ_0005576 Exerts an Oncogenic Role in Cervical Cancer via miR-1305-Dependent Regulation of PAIP1. PubMed 35378711
- Naunyn Schmiedebergs Arch Pharmacol, 2020 (first author): Inhibition of miR-574-5p suppresses cell growth and metastasis and enhances chemosensitivity by targeting RNA binding protein QKI in cervical cancer cells. PubMed 31786621
- Clin Exp Pharmacol Physiol, 2020 (first author): LncRNA PTCSC3 inhibits the proliferation, invasion and migration of cervical cancer cells via sponging miR-574-5p. PubMed 31587336
- Oncol Lett, 2017 (first author): OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia. PubMed 28521400
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion